Actinium Pharmaceuticals Stock Forecast, Price & News

-0.40 (-4.74 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume385,122 shs
Average Volume313,067 shs
Market Capitalization$162.17 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Actinium Pharmaceuticals logo

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.47 out of 5 stars

Medical Sector

643rd out of 2,097 stocks

Pharmaceutical Preparations Industry

313th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

Is Actinium Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Actinium Pharmaceuticals stock.
View analyst ratings for Actinium Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Actinium Pharmaceuticals?

Wall Street analysts have given Actinium Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Actinium Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Actinium Pharmaceuticals' next earnings date?

Actinium Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Actinium Pharmaceuticals

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its earnings results on Friday, May, 14th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.06. The biotechnology company had revenue of $0.62 million for the quarter.
View Actinium Pharmaceuticals' earnings history

How has Actinium Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Actinium Pharmaceuticals' stock was trading at $0.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATNM stock has increased by 3,245.8% and is now trading at $8.03.
View which stocks have been most impacted by COVID-19

When did Actinium Pharmaceuticals' stock split? How did Actinium Pharmaceuticals' stock split work?

Shares of Actinium Pharmaceuticals reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of Actinium Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for ATNM?

4 Wall Street analysts have issued 12 month price targets for Actinium Pharmaceuticals' stock. Their forecasts range from $25.00 to $57.00. On average, they expect Actinium Pharmaceuticals' share price to reach $41.00 in the next twelve months. This suggests a possible upside of 410.6% from the stock's current price.
View analysts' price targets for Actinium Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the following people:
  • Mr. Sandesh C. Seth M.B.A., M.S., MBA, Chairman & CEO (Age 57, Pay $893.19k)
  • Mr. Steven O'Loughlin BS, CFO & Corp. Sec. (Age 35, Pay $420k)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific & Technology Officer (Age 59, Pay $480k)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 66, Pay $515k)
  • Dr. David Gould, Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham, Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang, VP & Head of Radiation Sciences
  • Dr. Robert N. Daly M.S., Ph.D., VP & Head of Clinical Operations
  • Dr. Mamata Gokhale, VP & Global Head of Regulatory Affairs
  • Dr. Avinash Desai, Exec. VP of Clinical Devel., Operations & Medical Affairs

Who are some of Actinium Pharmaceuticals' key competitors?

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.26%), Silverarc Capital Management LLC (0.24%), GSA Capital Partners LLP (0.20%), Blair William & Co. IL (0.18%) and Rockefeller Capital Management L.P. (0.04%).
View institutional ownership trends for Actinium Pharmaceuticals

Which institutional investors are selling Actinium Pharmaceuticals stock?

ATNM stock was sold by a variety of institutional investors in the last quarter, including Silverarc Capital Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Actinium Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Actinium Pharmaceuticals stock?

ATNM stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Blair William & Co. IL, and Rockefeller Capital Management L.P..
View insider buying and selling activity for Actinium Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $8.03.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals has a market capitalization of $162.17 million. The biotechnology company earns $-22,220,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does Actinium Pharmaceuticals have?

Actinium Pharmaceuticals employs 32 workers across the globe.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com.

Where are Actinium Pharmaceuticals' headquarters?

Actinium Pharmaceuticals is headquartered at 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875 or via email at [email protected]

This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.